Henry Schein partners withTriMedand and Extremity teams to broaden orthopedics

Henry Schein announced plans to enter the upper- and lower-extremities specialty segment of the orthopedic market in line with our long-standing strategy. The Company announced that it has signed an agreement to acquire a majority interest in TriMed, a global developer of solutions for the orthopedic treatment of lower extremities, foot and ankle, and upper extremities, primarily hand and wrist . Headquartered in Santa Clarita, CA, TriMed had 2022 net sales of approximately $48M. The transaction is subject to certain regulatory approvals and closing conditions, and is expected to be completed in the first quarter of 2024. Henry Schein expects the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter. Financial terms were not disclosed. In addition, Henry Schein has entered into a strategic relationship with Extremity Medical , an innovative medical device company focused on developing new products for fusion, fixation, and motion preservation in the orthopedic treatment of the lower extremities and wrist. Headquartered in Parsippany, NJ, Extremity Medical will operate as a separate, stand-alone company. “Partnering with the TriMed and Extremity teams will provide Henry Schein with a platform to establish ourselves as a leading manufacturer and supplier in the Foot and Ankle as well as Hand and Wrist extremity segments of the orthopedic market,” said Stanley M. Bergman, Chairman and Chief Executive Officer, Henry Schein, Inc. “We believe the experienced leadership team that we have assembled is well-positioned to leverage our deep and longstanding relationships with existing integrated delivery network and ambulatory surgery center customers.”